Developmental Follow Up
The neurodevelopmental outcome of patients enrolled in FN3 will be assessed at 18-24 months of age using the Bayley Scales of Infant and Toddler Development. The test in it’s third edition (Bayley III), is arguably the most widely used objective test to measure neurocognitive development in young children. It provides a detailed performance-based assessment of a young child’s cognitive, language, and gross and fine motor development. The Bayley-III includes a parent-report that provides useful information about social-emotional and adaptive behavioral development.
As a network FN3 is collecting very important data with the collection of serum samples. The sample data, coupled with the results from Bailey III exams, will demonstrate a correlation between serum biomarker concentrations and outcomes. These results will also strongly support FN3’s theory that the concentrations of UCH-L1 and GFAP will decrease to concentrations comparable to controls over the first 24 hours of hypothermia, which allows the accuracy of predicting which infants will respond to therapeutic hypothermia. The neonates who will respond and have favorable outcomes will have lower pre-treatment GFAP and UCH-L1 concentrations than non-responders.